Examine how regulatory simplification in the medical devices sector can balance ease of doing business with patient safety. Discuss with reference to recent amendments to the Medical Devices Rules, 2017.

Medical devices in India are regulated by the Medical Devices Rules (MDR), 2017, framed under the Drugs and Cosmetics Act, 1940 and administered by CDSCO [1]. The amendments announced in August 2026 show that simplification and safety are complementary rather than competing, provided safeguards are retained.

Simplification: the ease-of-doing-business gains

• Rule 44 amended so that a manufacturer outsourcing sterilisation to a facility already holding a valid licence need not obtain a separate loan licence — removing duplicative dual licensing [4].
• Rule 63: the European Union is proposed for addition to the recognised "stringent regulatory jurisdictions" (USA, UK, Australia, Canada, Japan), enabling waiver of clinical investigation for devices lacking an Indian predicate [1][4].
• Uniform testing fees cut cost unpredictability, aiding MSMEs and start-ups without in-house sterilisation capacity [4].
• These operationalise the regulatory streamlining and single-window pillar of the National Medical Devices Policy, 2023 [2][3].

Safety: the safeguards built in

• The sterilisation site's licence number must be printed on the device label, preserving traceability and recall capability [4].
• A six-month transition for labelling change avoids abrupt disruption [4].
• Only a licensing step is withdrawn; testing, labelling, quality-system and CDSCO inspection obligations under MDR, 2017 continue [1].

Where the balance can slip

• Reliance-based approval presumes foreign clinical evidence is transferable to Indian populations and use settings; post-market surveillance becomes the real safety net [1].
• CDSCO's inspection and materiovigilance capacity must expand, else lighter entry controls remain unmatched by follow-up.
• Label-based traceability depends on field enforcement by State licensing authorities.

Thus, the reforms deregulate process duplication while retaining accountability, which is the correct design principle. Going forward, gains should be locked in by strengthening post-market surveillance, risk-based inspections and digital traceability, so that faster market access translates into the access, affordability and quality promised by NMDP 2023 [2] and the health goals under SDG-3.